Category Archives: CEO

Felipe Montoro Jens Views On The Future of Public-Private Partnerships in Brazil

Brazil has had to actively engage in the infrastructure sector in a bid to achieve modernization. The National Confederation of Industry (CNI) is also of the view that it was one of the best ways to assist Brazil in meeting its investment demands. Towards the end of June 2017, the first management project on Public-Private Partnerships (PPPs) and Concessions of the current mayor of Porto Alegre, Nelson Marchezan Júnior, were discussed by the Management Council of the Municipal Program of Partnerships (Propar).


According to Felipe Montoro Jens, an Infrastructure Project expert, subjects discussed at the meeting included sanitation projects, public lighting, Public Market, Guaíba Water Park, bidding for the concession of public clocks, as well as the construction of the Hospital Materno Infantil Presidente Vargas new headquarters. Also, the purpose of the meeting was to identify and define the services, areas, and priorities that the government is likely to seek partnerships with the private initiative in the future.

On May 2, 2017, Nelson Marchezan signed on a Decree 19736 to modernize the public administration which established the Municipal Program Partnerships (PROPAR / POA) and the Program Management Board Partnerships (CGP).

About Felipe Montoro Jens

When it comes to investments and finance, Felipe Montoro Jens is a reputed professional in these sectors. Currently, he serves as the Chief Executive Officer of Energizer Captacao S.A. Felipe also served as a Director at Santo Antonio Energia. Furthermore, in 2010 he held the Director position at Braskem S.A. Director until 2013. Felipe was also a board member of Concessionaria do Centro Administrativo do Distrito Federal before he was elected as the Chairman of the board.

Felipe Montoro Jens’ main area of specialization is in infrastructure. He is also concerned about high wastage levels in states because it negatively affects economic wealth. According to Felipe, the recent partnership will lead to waste reduction.

Ideamensch Interviews Clay Siegall

Clay Siegall is a co-founder of Seattle Genetics where he serves as the Board Chairman, President and CEO. He co-founded the company with his partner in 1998. A trained scientist, Clay Siegall attended the George Washington University where studied genetics and the University of Maryland where he studied Zoology. Clay recently held an interview session with Ideamensch where he discussed his involvement with Seattle Genetics. According to him, decided to start the company after watching his father suffer from cancer when he was a small boy. Clay then decided to improve the small resources and tools that are used in treating cancer by oncologists and other specialists.

On the question of what makes him to be more productive, Clay Siegall said that he reminds himself constantly he does not know all the things and that he is the process of learning. He stated that he is a great team worker and he likes to interact with people who are smart so as to gain more information. According to Clay Siegall, having an open mind is an important aspect when it comes to business success. An established author, Clay Siegall has over the years co-authored and authored more than 70 publications on medicine and science.

Clay Siegall works with other medical institutions such as Ultragenyx Pharmaceutical, Washington Roundtable, and also Alder BioPharmaceuticals. A non-profit organization, the Washington Roundtable involves CEOs coming from the biggest employers in the Washington State. Clay got the Maryland Alumnus of the Year for Computer, Math and Natural Sciences because of his contributions to biotechnology pioneering and cancer research. Because of the growth of Seattle Genetics, Clay Siegall received the distinction of the Pacific Northwest Ernst & Young Entrepreneur of the Year. Dr. Siegall has an experience of over 20 years in both cancer research and therapeutic drug development.

Clay Siegall was once a Senior Research Investigator with the Bristol-Myers Squibb Pharmaceutical research Institute. He is the Director at WBBA (Washington Biotechnology and Biomedical Association). At Mirna Therapeutics, Inc, Clay Siegall serves as anon Executive Director. He works in the Board of Editors at 3 scientific journals and also is in the Board at the Scientific Counselors for the Cancer Treatment Research Foundation.